Market Cap 244.89M
Revenue (ttm) 5.72M
Net Income (ttm) -75.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,318.36%
Debt to Equity Ratio 0.00
Volume 184,346
Avg Vol 596,258
Day's Range N/A - N/A
Shares Out 63.28M
Stochastic %K 11%
Beta 1.53
Analysts Strong Sell
Price Target $6.40

Company Profile

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically val...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 900 4690
Address:
500 West 5th Street, Suite 1200, Austin, United States
senior_nurse
senior_nurse Jan. 29 at 12:34 AM
$STTK — desperate attempts to save the stock from fading down.
0 · Reply
notreload_ai
notreload_ai Jan. 28 at 4:03 PM
Piper Sandler begins coverage of $STTK with an Overweight rating and $15 target, highlighting promise of SL-325 ahead of Phase 1 data. https://notreload.xyz/piper-sandler-starts-coverage-on-shattuck-labs-with-bullish-view/
0 · Reply
JFais
JFais Jan. 28 at 2:59 PM
$STTK (NP) $700MC (fully diluted), $550M EV (with warrants exercised) Running up into Q2 data for SL-325 (first DR3 blocking antibody in clinic) Big idea = they can achieve more potent & durable blockade vs competitors solely pursuing TL1A (Roche $ROIV $7B comp comes to mind)
0 · Reply
senior_nurse
senior_nurse Jan. 26 at 7:59 PM
$STTK EddiePlaysHarder, Why don't you add - and, by the way, I am a front-runner.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 22 at 12:48 PM
$STTK RSI: 65.22, MACD: 0.4316 Vol: 0.59, MA20: 4.06, MA50: 3.10 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DaBullRunner
DaBullRunner Jan. 14 at 5:04 PM
$STTK hope you listened to me here👇 🚨CRIS🚨Hope you don’t ignore me here 👈
0 · Reply
senior_nurse
senior_nurse Jan. 13 at 1:31 AM
$STTK — runs like a classic flow-driven rally: early entry by bigger traders/algos creates a sharp uptick, retail sees the move and buys, volume spikes, then the horizon broadens. Once that new buyer cohort slows and distribution begins, the same stronger hands can sell into the enthusiasm and leave late buyers holding the bag. Not saying manipulation, just saying this price action looks like momentum + rotation — and these patterns often fail hard when demand disappears.
0 · Reply
StockScanners
StockScanners Jan. 10 at 4:24 AM
$STTK reached 4.94
0 · Reply
senior_nurse
senior_nurse Jan. 8 at 9:31 PM
$STTK Here we go. This was not organic drift A new buyer cohort showed up (momentum traders, algos, retail chasing). Phase-1, single-asset biotech. No new clinical data released. Move driven by flow + attention, not fundamentals. What usually happens next (historically) For early-stage biotech like STTK: Not an immediate crash. First a failed breakout. Then a slow bleed. Then one air-pocket drop when liquidity disappears
0 · Reply
StockScanners
StockScanners Jan. 8 at 7:19 AM
$STTK keep watch if this holds above 4.60
0 · Reply
Latest News on STTK
senior_nurse
senior_nurse Jan. 29 at 12:34 AM
$STTK — desperate attempts to save the stock from fading down.
0 · Reply
notreload_ai
notreload_ai Jan. 28 at 4:03 PM
Piper Sandler begins coverage of $STTK with an Overweight rating and $15 target, highlighting promise of SL-325 ahead of Phase 1 data. https://notreload.xyz/piper-sandler-starts-coverage-on-shattuck-labs-with-bullish-view/
0 · Reply
JFais
JFais Jan. 28 at 2:59 PM
$STTK (NP) $700MC (fully diluted), $550M EV (with warrants exercised) Running up into Q2 data for SL-325 (first DR3 blocking antibody in clinic) Big idea = they can achieve more potent & durable blockade vs competitors solely pursuing TL1A (Roche $ROIV $7B comp comes to mind)
0 · Reply
senior_nurse
senior_nurse Jan. 26 at 7:59 PM
$STTK EddiePlaysHarder, Why don't you add - and, by the way, I am a front-runner.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 22 at 12:48 PM
$STTK RSI: 65.22, MACD: 0.4316 Vol: 0.59, MA20: 4.06, MA50: 3.10 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DaBullRunner
DaBullRunner Jan. 14 at 5:04 PM
$STTK hope you listened to me here👇 🚨CRIS🚨Hope you don’t ignore me here 👈
0 · Reply
senior_nurse
senior_nurse Jan. 13 at 1:31 AM
$STTK — runs like a classic flow-driven rally: early entry by bigger traders/algos creates a sharp uptick, retail sees the move and buys, volume spikes, then the horizon broadens. Once that new buyer cohort slows and distribution begins, the same stronger hands can sell into the enthusiasm and leave late buyers holding the bag. Not saying manipulation, just saying this price action looks like momentum + rotation — and these patterns often fail hard when demand disappears.
0 · Reply
StockScanners
StockScanners Jan. 10 at 4:24 AM
$STTK reached 4.94
0 · Reply
senior_nurse
senior_nurse Jan. 8 at 9:31 PM
$STTK Here we go. This was not organic drift A new buyer cohort showed up (momentum traders, algos, retail chasing). Phase-1, single-asset biotech. No new clinical data released. Move driven by flow + attention, not fundamentals. What usually happens next (historically) For early-stage biotech like STTK: Not an immediate crash. First a failed breakout. Then a slow bleed. Then one air-pocket drop when liquidity disappears
0 · Reply
StockScanners
StockScanners Jan. 8 at 7:19 AM
$STTK keep watch if this holds above 4.60
0 · Reply
NyseDayTrader
NyseDayTrader Jan. 7 at 8:47 PM
$STTK i hate mistakes
0 · Reply
NyseDayTrader
NyseDayTrader Jan. 7 at 8:20 PM
$STTK @!&@! !!!!
0 · Reply
hitmongreen
hitmongreen Jan. 7 at 3:38 PM
$STTK nonstop gains
0 · Reply
senior_nurse
senior_nurse Jan. 6 at 9:03 PM
$STTK — FYI anachartanalyst isn’t a real analyst. It’s an automated bot tied to AnaChart that auto-generates technical charts, indicators, and price targets. No human judgment, no fundamental research, no accountability — noise, not real analysis.
0 · Reply
anachartanalyst
anachartanalyst Jan. 6 at 8:02 PM
$STTK https://anachart.com/wp-content/uploads/ana_temp/1767729729_soc-img.jpg
0 · Reply
senior_nurse
senior_nurse Jan. 6 at 7:38 PM
$STTK — still a Phase-1, single-asset biotech with no patient efficacy data and a long wait to meaningful readouts, trading more on narrative and momentum than fundamentals, which can quietly fade as attention shifts.
0 · Reply
DARKP00L
DARKP00L Jan. 6 at 7:13 PM
$STTK 13:40 on Jan. 06 2026 Citigroup Maintains Neutral on Shattuck Labs, Raises Price Target to $4 #tradeideas
0 · Reply
NyseDayTrader
NyseDayTrader Jan. 6 at 2:21 PM
$STTK this has just been chugging along
0 · Reply
hitmongreen
hitmongreen Jan. 5 at 6:06 PM
$STTK hell of a run so far
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 7:09 PM
$STTK Current Stock Price: $3.66 Contracts to trade: $2.5 STTK Jan 16 2026 Call Entry: $1.08 Exit: $1.36 ROI: 26% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
senior_nurse
senior_nurse Dec. 30 at 6:08 AM
$STTK — single-asset biotech, lead drug only Phase 1 in healthy volunteers with no patient data until ~Q2’26; runway assumes dilution, crowded inflammatory bowel disease space, and momentum reversals here can be sudden and painful.
1 · Reply
TacticalCycleInvestor
TacticalCycleInvestor Dec. 27 at 7:23 AM
$STTK Risk tolerance remains selective and tied closely to execution credibility. Cash discipline will likely dictate investor patience. Missteps now carry a higher penalty than in prior cycles. Investors will likely insist on proof before expanding exposure.
0 · Reply